New therapy promising for melanoma skin cancer
The combination of two different biotherapies may be beneficial for patients with inoperable melanoma, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. – The combination of two different biotherapies (interferon alfa-2b and tremelimumab) may be beneficial for patients with inoperable melanoma, revealed by researchers in US.